Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP2D6 | P10635 | 1/20 | 0.67 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.67 |
| ▸ | INPP5D | Q92835 | 1/20 | 0.66 |
| ▸ | CDC25A | P30304 | 5/20 | 0.61 |
| ▸ | POLA1 | P09884 | 1/20 | 0.60 |
| ▸ | NPC1L1 | Q9UHC9 | 3/20 | 0.57 |
| ▸ | GRIN2A | Q12879 | 2/20 | 0.57 |
| ▸ | GRIN1 | Q05586 | 1/20 | 0.57 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.57 |
| ▸ | OSBP | P22059 | 1/20 | 0.55 |
| ▸ | OSBP2 | Q969R2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | USP2 | O75604 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.55 |
| ▸ | TP53 | P04637 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | SRD5A1 | P18405 | 4/20 | 0.54 |
| ▸ | SRD5A2 | P31213 | 3/20 | 0.54 |
| ▸ | FNTA | P49354 | 1/20 | 0.54 |
| ▸ | FNTB | P49356 | 1/20 | 0.54 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16860684 | 1.00 | CYP2D6 (0.67) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL21257887 | 0.91 | GRIN2A (0.57) | CYP2D6CYP2C19INPP5DCDC25AGRIN2A | |
| SCHEMBL8575259 | 0.91 | GRIN2A (0.68) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL20390519 | 0.91 | GRIN2A (0.68) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL18376473 | 0.91 | GRIN2A (0.68) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL1358415 | 0.88 | GRIN2A (0.59) | CYP2D6CYP2C19INPP5DGRIN2AGRIN1 | |
| SCHEMBL232939 | 0.88 | GPBAR1 (0.57) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL24710130 | 0.88 | GRIN2A (0.74) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL20367591 | 0.88 | GRIN2A (0.74) | CYP2D6CYP2C19INPP5DCDC25APOLA1 | |
| SCHEMBL21257629 | 0.87 | GRIN2A (0.58) | CYP2D6CYP2C19INPP5DGRIN2AGRIN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20020183283-A1 | Meiosis regulating compounds | FAARUP PETER (DK) | 2002-12-05 | — | — | US | claimed |
| CN-116497082-B | Method for synthesizing 3 alpha, 7 alpha, 24R-trihydroxy cholesterol by chemical-enzymatic method | 华南理工大学 | 2023-09-29 | — | — | CN | disclosed |
| EP-3368024-B1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES INC (US) | 2023-09-20 | — | — | EP | disclosed |
| CN-116497082-A | Method for synthesizing 3 alpha, 7 alpha, 24R-trihydroxy cholesterol by chemical-enzymatic method | 华南理工大学 | 2023-07-28 | — | — | CN | disclosed |
| CN-115813794-A | Method for improving hair quality by improving scalp health | 宝洁公司 | 2023-03-21 | — | — | CN | disclosed |
| CN-114315947-A | Novel method for synthesizing cholesterol and 25-hydroxycholesterol by using 22-sterol as raw material | 上海敏韬医药科技有限公司 | 2022-04-12 | — | — | CN | disclosed |
| US-20220054429-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | AKOS BIOSCIENCES, INC. | 2022-02-24 | — | — | US | disclosed |
| EP-3368024-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | Jay Pharma, Inc. (CA) | 2018-09-05 | — | — | EP | disclosed |
| WO-2017072773-A1 | COMPOSITIONS COMPRISING CANNABIDIOL AND SECOND THERAPEUTIC AGENTS FOR THE TREATMENT OF CANCER | NATHAN ILANA (IL) | 2017-05-04 | — | — | WO | disclosed |
| WO-2011006087-A1 | INHIBITION OF PPAR GAMMA EXPRESSION IN PREADIPOCYTE CELLS BY OXYSTEROLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2011-01-13 | — | — | WO | disclosed |
| EP-2111225-A2 | INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS | The Regents Of The University Of California (US) | 2009-10-28 | — | — | EP | disclosed |
| WO-2008082520-A2 | INHIBITION OF PPAR GAMMA EXPRESSION BY SPECIFIC OSTEOGENIC OXYSTEROLS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2008-07-10 | — | — | WO | disclosed |
| EP-0735992-B1 | METHOD OF CONVERTING HYDROXYL GROUPS INTO CORRESPONDING FLUORO COMPOUNDS | BAYER AG (DE) | 2001-01-03 | — | — | EP | disclosed |
| US-5760255-A | Process for the conversion of hydroxyl groups into the corresponding fluorine compounds | BAYER AG (DE) | 1998-06-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020183283-A1 | Meiosis regulating compounds | SREBF2, SREBF1, TRIP13 | CYP2D6 3846/4885CYP2C19 4130/4885INPP5D 1443/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.